Among the various TrkB-targeting strategies under investigation for glaucoma [13–15, 44], the bicistronic AAV vector expressing both human TrkB and mBDNF offers distinct translational advantages, including simplified dosing, controlled stoichiometry, and robust target engagement. The gene discussed is NTRK2; the disease is glaucoma.